Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Double-blind, Randomised, Placebo-controlled Trial to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of DT-101 in Adults With Major Depressive Disorder Receiving Pharmacological Therapy for Depression

NCT07610473 is registered in ClinicalTrials.gov with Draig Therapeutics Ltd as lead sponsor.

NCT NCT07610473
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07610473 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Double-blind, Randomised, Placebo-controlled Trial to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of DT-101 in Adults With Major Depressive Disorder Receiving Pharmacological Therapy for Depression
Lead sponsor
Draig Therapeutics Ltd
Phase
Phase 2
Overall status
Recruiting
Start date
May 14, 2026
Completion date
May 31, 2027
Enrollment
118 (estimated)
Sites
23

Conditions

As the registry lists them; a condition with its own page is linked.

major depressive disorder (mdd)